> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Novid Distributing Unapproved, Misbranded Drug: FDA
- URL: https://www.fdaweb.com/novid-distributing-unapproved-misbranded-drug-fda/
- Published: 2023-12-13T12:00:00.000Z
- Updated: 2026-09-14T14:18:35.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5155981

FDA says Novid Group in Northridge, CA, is distributing an over-the-counter combination antihistamine and nasal decongestant, novid Nasal Spray, through its Web site. A 12/7 [Warning Letter](https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/novid-group-inc-672251-12072023?ref=fdaweb.com) says the product is illegally distributed because it is an unapproved new drug that also is misbranded.

The letter contains claims from the company Web site that provide evidence of the product’s intended use as a drug to diagnose, cure, mitigate, treat, or prevent disease.

According to FDA, the novid product is not formulated or labeled according to the requirements in the applicable over-the-counter drug monograph.

The product is misbranded, the letter says, because it is a nonprescription drug that does not comply with the requirements for marketing under the Federal Food, Drug, and Cosmetic Act.

Novid Group was told to respond with a list of specific actions it has taken to correct the violations and prevent their recurrence, with related documentation and a schedule for completing the corrections.